Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
Craig TJ, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, Jacobs JS, Yang WH, Ritchie B, Aygören-Pürsün E, Keith PK, Busse P, Feuersenger H, Alexandru Bica M, Jacobs I, Pragst I, Magerl M.
Craig TJ, et al. Among authors: yang wh.
Lancet Haematol. 2024 May 3:S2352-3026(24)00081-4. doi: 10.1016/S2352-3026(24)00081-4. Online ahead of print.
Lancet Haematol. 2024.
PMID: 38710185